Robert Hershberg, MD, PhD
Executive Vice President and Head of Business Development and Global Alliances at Celgene
Robert M. Hershberg currently serves as a member of the Executive Committee at Celgene and is responsible for business development in all therapeutic areas within the Celgene portfolio. Prior to his current role, Rob served as Chief Scientific Officer at Celgene. He joined Celgene in August 2014 to lead the scientific and early clinical efforts in Immuno-Oncology (I-O) and established a Therapeutic Center of Excellence for I-O in Seattle.
Prior to joining Celgene, Rob was the President and Chief Executive Officer of VentiRx Pharmaceuticals, a clinical stage biopharmaceutical company, which he co-founded in 2006. Prior to co-founding VentiRx, Dr. Hershberg served as Senior Vice President and Chief Medical Officer at Dendreon Corporation, a biotechnology company, where he led the clinical, regulatory and biometrics groups, focusing on the development of Provenge® in metastatic prostate cancer. From 2001 to 2003, Dr. Hershberg was the Vice President of Medical Genetics at Corixa, a pharmaceutical company (acquired by GlaxoSmithKline in 2005).
Earlier in his career, Dr. Hershberg served as an Assistant Professor at Harvard Medical School and an Associate Physician at the Brigham and Women’s Hospital in Boston, Massachusetts. Dr. Hershberg holds clinical and research faculty positions at the University of Washington School of Medicine and is a member of the board of directors of Adaptive Biotechnologies Corp., Nanostring Technology (NASDAQ: NSTG) and Silverback Therapeutics. He completed his undergraduate degree in molecular biology and medical degree (M.D.) at UCLA, and his Ph.D. in biology at the Salk Institute.